Next-Generation Sequencing and Result Interpretation in Clinical Oncology

Challenges of Personalized Cancer Therapy

Yekaterina B. Khotskaya, Gordon Mills, Kenna R. Mills Shaw

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The tools of next-generation sequencing (NGS) technology, such as targeted sequencing of candidate cancer genes and whole-exome and-genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeutics and biomarker-guided clinical trials, are fueling further technological advancements of NGS technology. However, NGS data interpretation is associated with challenges that must be overcome to promote the techniques' effective integration into clinical oncology practice. Specifically, sequencing of a patient's tumor often yields 30-65 somatic variants, but most of these variants are "passenger" mutations that are phenotypically neutral and thus not targetable. Therefore, NGS data must be interpreted by multidisciplinary decision-support teams to determine mutation actionability and identify potential "drivers," so that the treating physician can prioritize what clinical decisions can be pursued in order to provide cancer therapy that is personalized to the patient and his or her unique genome.

Original languageEnglish (US)
Pages (from-to)113-125
Number of pages13
JournalAnnual Review of Medicine
Volume68
DOIs
StatePublished - Jan 14 2017
Externally publishedYes

Fingerprint

Oncology
Medical Oncology
Genes
Genome
Exome
Technology
Mutation
Neoplasm Genes
Therapeutic Uses
Neoplasms
Fueling
Biomarkers
Clinical Trials
Physicians
Tumors
Therapeutics

Keywords

  • Decision support
  • Driver mutations
  • Passenger mutations
  • Variant actionability

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Next-Generation Sequencing and Result Interpretation in Clinical Oncology : Challenges of Personalized Cancer Therapy. / Khotskaya, Yekaterina B.; Mills, Gordon; Mills Shaw, Kenna R.

In: Annual Review of Medicine, Vol. 68, 14.01.2017, p. 113-125.

Research output: Contribution to journalArticle

@article{36a1bd2f05714f809976373213a99743,
title = "Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy",
abstract = "The tools of next-generation sequencing (NGS) technology, such as targeted sequencing of candidate cancer genes and whole-exome and-genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeutics and biomarker-guided clinical trials, are fueling further technological advancements of NGS technology. However, NGS data interpretation is associated with challenges that must be overcome to promote the techniques' effective integration into clinical oncology practice. Specifically, sequencing of a patient's tumor often yields 30-65 somatic variants, but most of these variants are {"}passenger{"} mutations that are phenotypically neutral and thus not targetable. Therefore, NGS data must be interpreted by multidisciplinary decision-support teams to determine mutation actionability and identify potential {"}drivers,{"} so that the treating physician can prioritize what clinical decisions can be pursued in order to provide cancer therapy that is personalized to the patient and his or her unique genome.",
keywords = "Decision support, Driver mutations, Passenger mutations, Variant actionability",
author = "Khotskaya, {Yekaterina B.} and Gordon Mills and {Mills Shaw}, {Kenna R.}",
year = "2017",
month = "1",
day = "14",
doi = "10.1146/annurev-med-102115-021556",
language = "English (US)",
volume = "68",
pages = "113--125",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Next-Generation Sequencing and Result Interpretation in Clinical Oncology

T2 - Challenges of Personalized Cancer Therapy

AU - Khotskaya, Yekaterina B.

AU - Mills, Gordon

AU - Mills Shaw, Kenna R.

PY - 2017/1/14

Y1 - 2017/1/14

N2 - The tools of next-generation sequencing (NGS) technology, such as targeted sequencing of candidate cancer genes and whole-exome and-genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeutics and biomarker-guided clinical trials, are fueling further technological advancements of NGS technology. However, NGS data interpretation is associated with challenges that must be overcome to promote the techniques' effective integration into clinical oncology practice. Specifically, sequencing of a patient's tumor often yields 30-65 somatic variants, but most of these variants are "passenger" mutations that are phenotypically neutral and thus not targetable. Therefore, NGS data must be interpreted by multidisciplinary decision-support teams to determine mutation actionability and identify potential "drivers," so that the treating physician can prioritize what clinical decisions can be pursued in order to provide cancer therapy that is personalized to the patient and his or her unique genome.

AB - The tools of next-generation sequencing (NGS) technology, such as targeted sequencing of candidate cancer genes and whole-exome and-genome sequencing, coupled with encouraging clinical results based on the use of targeted therapeutics and biomarker-guided clinical trials, are fueling further technological advancements of NGS technology. However, NGS data interpretation is associated with challenges that must be overcome to promote the techniques' effective integration into clinical oncology practice. Specifically, sequencing of a patient's tumor often yields 30-65 somatic variants, but most of these variants are "passenger" mutations that are phenotypically neutral and thus not targetable. Therefore, NGS data must be interpreted by multidisciplinary decision-support teams to determine mutation actionability and identify potential "drivers," so that the treating physician can prioritize what clinical decisions can be pursued in order to provide cancer therapy that is personalized to the patient and his or her unique genome.

KW - Decision support

KW - Driver mutations

KW - Passenger mutations

KW - Variant actionability

UR - http://www.scopus.com/inward/record.url?scp=85009956018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009956018&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-102115-021556

DO - 10.1146/annurev-med-102115-021556

M3 - Article

VL - 68

SP - 113

EP - 125

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -